Skip to main content
Indivior PLC logo

Indivior PLC — Investor Relations & Filings

Ticker · INDV ISIN · GB00BN4HT335 LEI · 213800V3NCQTY7IED471 IL Manufacturing
Open in API
Filings indexed 1,983 across all filing types
Latest filing 2024-05-10 Regulatory Filings
Country GB United Kingdom
Listing IL INDV

About Indivior PLC

https://www.indivior.com/en

Indivior PLC is a global pharmaceutical company that develops, manufactures, and sells medicines to treat substance use disorders (SUD) and serious mental illnesses. The company's primary focus is on pioneering treatments for opioid use disorder (OUD), with a portfolio centered on buprenorphine-based prescription pharmaceuticals. Through its research and development efforts, Indivior aims to address the complex challenges of addiction and behavioral health by providing innovative, life-transforming therapies for patients worldwide.

Recent filings

Filing Released Lang Actions
BLOCK LISTING INTERIM REVIEW
Regulatory Filings
2024-05-10 English
BOARD COMMITTEE CHANGES
Regulatory Filings
2024-05-10 English
TRANSACTION IN OWN SHARES
Regulatory Filings
2024-05-10 English
Block listing Interim Review
Share Issue/Capital Change Classification · 99% confidence The document is explicitly titled 'BLOCK LISTING SIX MONTHLY RETURN' and is issued via 'RNS Number : 9813N' on May 10, 2024. It details the movement of unallotted securities under various employee incentive plans (Long-Term Incentive Plan, Share Option Plan, Employee Stock Purchase Plan) over a six-month period (November 10, 2023, to May 9, 2024). This type of periodic return concerning the balance of securities available for allotment under employee schemes is a specific regulatory filing requirement, often associated with listing rules (indicated by the reference to LR3.5.7G). Since it is a specific regulatory filing that doesn't fit the definitions for 10-K, ER, IR, or DIRS, the most appropriate general category for a mandatory, periodic regulatory disclosure that isn't a primary financial report is 'Regulatory Filings' (RNS). Although it relates to share capital, it is a compliance return, not a direct share issue announcement (SHA) or transaction report (POS). Given the RNS header and the nature of the required return, RNS is the best fit.
2024-05-10 English
Board Committee Changes
Board/Management Information Classification · 98% confidence The document is an official announcement from Indivior PLC, identified by the 'RNS Number' header and the closing statement referencing RNS as the news service of the London Stock Exchange. The content explicitly details changes to the company's Board Committee membership (Nomination, Remuneration, and Science Committees), including appointments and resignations of directors. This directly corresponds to the definition of Board/Management Information (MANG). Although it is distributed via RNS, the core subject matter is management/board changes, making MANG the most specific classification over the general RNS fallback.
2024-05-10 English
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document is titled "TRANSACTIONS IN OWN SHARES" and explicitly states that INDIVIOR PLC purchased a specific number of its ordinary shares for cancellation on May 9, 2024. It details the number of shares purchased, the highest, lowest, and VWAP prices, and provides a full breakdown of individual purchases. This content directly corresponds to the definition of a report detailing the company buying back or selling its own shares, which maps to the 'Transaction in Own Shares' category (POS). The presence of the RNS Number and the closing statement referencing RNS and the FCA confirms it is a regulatory disclosure, but the specific content dictates the most precise classification.
2024-05-10 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.